JOHNSON & JOHNSON

NYSE: JNJ (Johnson & Johnson)

Kemas kini terakhir: 7 jam lalu

202.48

-2.85 (-1.39%)

  • 1H -1.39%
  • 5H -2.45%
  • 1B 8.36%
  • 6B 32.15%
  • Tahun Ke Tarikh 40.59%
  • 1T 34.57%
  • 5T 34.74%
Penutupan Terdahulu 205.33
Buka 204.59
Jumlah Dagangan 6,252,878
Purata Dagangan (3B) 8,751,346
Modal Pasaran 487,834,058,752
Harga / Pendapatan (P/E TTM) 19.56
Harga / Pendapatan (P/E Ke hadapan) 17.86
Harga / Jualan (P/S) 5.41
Harga / Buku (P/B) 6.24
Julat 52 Minggu
140.68 (-30%) — 207.81 (2%)
Tarikh Pendapatan 21 Jan 2026
Hasil Dividen (DY TTM) 0.61%
Margin Keuntungan 25.00%
Margin Operasi (TTM) 28.26%
EPS Cair (TTM) 9.34
Pertumbuhan Hasil Suku Tahunan (YOY) 5.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 18.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 66.90%
Nisbah Semasa (MRQ) 1.26
Aliran Tunai Operasi (OCF TTM) 24.78 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 16.80 B
Pulangan Atas Aset (ROA TTM) 7.77%
Pulangan Atas Ekuiti (ROE TTM) 29.45%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Johnson & Johnson Menaik Menaik

AISkor Stockmoo

0.9
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam 3.0
Volatiliti Harga -3.0
Purata Bergerak Teknikal -1.0
Osilator Teknikal 4.0
Purata 0.90

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
JNJ 488 B 0.61% 19.56 6.24
ABBV 402 B 1.44% 172.39 50.46
MRK 252 B 1.60% 13.36 4.55
PFE 146 B 1.67% 14.94 1.55
BMY 106 B 1.19% 17.49 5.40
GSK 97 B 0.81% 13.71 4.52

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.06%
% Dimiliki oleh Institusi 74.08%
Julat 52 Minggu
140.68 (-30%) — 207.81 (2%)
Julat Harga Sasaran
190.00 (-6%) — 215.00 (6%)
Tinggi 215.00 (Citigroup, 6.18%) Beli
Median 204.00 (0.75%)
Rendah 190.00 (Freedom Capital Markets, -6.16%) Pegang
190.00 (Morgan Stanley, -6.16%) Pegang
190.00 (Stifel, -6.16%) Pegang
Purata 202.46 (-0.01%)
Jumlah 6 Beli, 7 Pegang
Harga Purata @ Panggilan 189.69
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Barclays 02 Dec 2025 197.00 (-2.71%) Pegang 205.42
Freedom Capital Markets 22 Oct 2025 190.00 (-6.16%) Pegang 192.94
B of A Securities 15 Oct 2025 204.00 (0.75%) Pegang 191.17
03 Oct 2025 198.00 (-2.21%) Pegang 188.64
Citigroup 15 Oct 2025 215.00 (6.18%) Beli 191.17
07 Oct 2025 213.00 (5.20%) Beli 188.89
Morgan Stanley 15 Oct 2025 190.00 (-6.16%) Pegang 191.17
10 Oct 2025 178.00 (-12.09%) Pegang 190.72
Raymond James 15 Oct 2025 209.00 (3.22%) Beli 191.17
Stifel 15 Oct 2025 190.00 (-6.16%) Pegang 191.17
UBS 14 Oct 2025 214.00 (5.69%) Beli 190.85
Goldman Sachs 09 Oct 2025 212.00 (4.70%) Beli 191.08
Bernstein 06 Oct 2025 193.00 (-4.68%) Pegang 188.16
Wells Fargo 03 Oct 2025 212.00 (4.70%) Beli 188.64
Guggenheim 23 Sep 2025 206.00 (1.74%) Beli 176.58
JP Morgan 16 Sep 2025 200.00 (-1.22%) Pegang 176.46
Papar semua
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
MORIKIS JOHN G 207.56 - 1,250 259,450
Jumlah Keseluruhan Kuantiti Bersih 1,250
Jumlah Keseluruhan Nilai Bersih ($) 259,450
Purata Pembelian Keseluruhan ($) 207.56
Purata Jualan Keseluruhan ($) -
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
MORIKIS JOHN G Pengarah 26 Nov 2025 Beli (+) 1,250 207.56 259,450
  • 3M
Tarikh Jenis Butiran
03 Dec 2025 Pengumuman Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40
17 Nov 2025 Pengumuman New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
17 Nov 2025 Pengumuman Johnson & Johnson Set to Revolutionize the Treatment of Cancer With the Acquisition of Halda Therapeutics
06 Nov 2025 Pengumuman DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma
06 Nov 2025 Pengumuman FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder
05 Nov 2025 Pengumuman Johnson & Johnson to Participate in the Citi’s 2025 Global Healthcare Conference
03 Nov 2025 CNBC Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant
29 Oct 2025 Pengumuman Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting
27 Oct 2025 Pengumuman New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile
27 Oct 2025 Pengumuman Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
27 Oct 2025 Pengumuman TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years
24 Oct 2025 Pengumuman Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies
24 Oct 2025 Pengumuman Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis
22 Oct 2025 Pengumuman Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference
19 Oct 2025 Pengumuman Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer
16 Oct 2025 Pengumuman TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care
14 Oct 2025 Pengumuman Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
14 Oct 2025 Pengumuman Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
14 Oct 2025 Pengumuman Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
10 Oct 2025 Pengumuman Johnson & Johnson recommends shareholders reject “mini-tender” offer by Tutanota
10 Oct 2025 Pengumuman Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
09 Oct 2025 Pengumuman Johnson & Johnson to Participate in the UBS Global Healthcare Conference
07 Oct 2025 Pengumuman TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis
07 Oct 2025 Pengumuman Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses
07 Oct 2025 Pengumuman Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill
06 Oct 2025 Pengumuman Johnson & Johnson to Participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
29 Sep 2025 Pengumuman U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor
19 Sep 2025 Pengumuman TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
19 Sep 2025 Pengumuman TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
17 Sep 2025 Pengumuman Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis
15 Sep 2025 Pengumuman Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
09 Sep 2025 Pengumuman U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated
08 Sep 2025 Pengumuman Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors
08 Sep 2025 Pengumuman Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum
07 Sep 2025 Pengumuman Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer
06 Sep 2025 Pengumuman RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
Papar semua
Hasil Dividen (DY TTM) 0.61%
Purata Hasil Dividen 5T 2.78%
Nisbah Pembayaran 53.75%
Jangkaan Pembayaran Dividen Seterusnya Dec 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
18 Feb 2025 02 Jan 2025 04 Mar 2025 1.24 Tunai
26 Nov 2024 15 Oct 2024 10 Dec 2024 1.24 Tunai
27 Aug 2024 17 Jul 2024 10 Sep 2024 1.24 Tunai
20 May 2024 16 Apr 2024 04 Jun 2024 1.24 Tunai
16 Feb 2024 02 Jan 2024 05 Mar 2024 1.19 Tunai
20 Nov 2023 19 Oct 2023 05 Dec 2023 1.19 Tunai
25 Aug 2023 20 Jul 2023 07 Sep 2023 1.19 Tunai
22 May 2023 18 Apr 2023 06 Jun 2023 1.19 Tunai
17 Feb 2023 03 Jan 2023 07 Mar 2023 1.13 Tunai
21 Nov 2022 19 Oct 2022 06 Dec 2022 1.13 Tunai
22 Aug 2022 18 Jul 2022 06 Sep 2022 1.13 Tunai
23 May 2022 19 Apr 2022 07 Jun 2022 1.13 Tunai
18 Feb 2022 04 Jan 2022 08 Mar 2022 1.06 Tunai
22 Nov 2021 21 Oct 2021 07 Dec 2021 1.06 Tunai
23 Aug 2021 19 Jul 2021 07 Sep 2021 1.06 Tunai
24 May 2021 06 May 2021 08 Jun 2021 1.06 Tunai
22 Feb 2021 04 Jan 2021 09 Mar 2021 1.01 Tunai
23 Nov 2020 22 Oct 2020 08 Dec 2020 1.01 Tunai
24 Aug 2020 20 Jul 2020 08 Sep 2020 1.01 Tunai
22 May 2020 14 Apr 2020 09 Jun 2020 1.01 Tunai
24 Feb 2020 02 Jan 2020 10 Mar 2020 0.95 Tunai
25 Nov 2019 18 Oct 2019 10 Dec 2019 0.95 Tunai
26 Aug 2019 16 Jul 2019 10 Sep 2019 0.95 Tunai
24 May 2019 26 Apr 2019 11 Jun 2019 0.95 Tunai
25 Feb 2019 02 Jan 2019 12 Mar 2019 0.9 Tunai
26 Nov 2018 18 Oct 2018 11 Dec 2018 0.9 Tunai
27 Aug 2018 17 Jul 2018 11 Sep 2018 0.9 Tunai
25 May 2018 26 Apr 2018 12 Jun 2018 0.9 Tunai
26 Feb 2018 02 Jan 2018 13 Mar 2018 0.84 Tunai
27 Nov 2017 19 Oct 2017 12 Dec 2017 0.84 Tunai
25 Aug 2017 17 Jul 2017 12 Sep 2017 0.84 Tunai
25 May 2017 27 Apr 2017 13 Jun 2017 0.84 Tunai
24 Feb 2017 03 Jan 2017 14 Mar 2017 0.8 Tunai
18 Nov 2016 20 Oct 2016 06 Dec 2016 0.8 Tunai
19 Aug 2016 18 Jul 2016 06 Sep 2016 0.8 Tunai
20 May 2016 28 Apr 2016 07 Jun 2016 0.8 Tunai
19 Feb 2016 04 Jan 2016 08 Mar 2016 0.75 Tunai
20 Nov 2015 22 Oct 2015 08 Dec 2015 0.75 Tunai
21 Aug 2015 20 Jul 2015 08 Sep 2015 0.75 Tunai
21 May 2015 23 Apr 2015 09 Jun 2015 0.75 Tunai
20 Feb 2015 05 Jan 2015 10 Mar 2015 0.7 Tunai
21 Nov 2014 16 Oct 2014 09 Dec 2014 0.7 Tunai
22 Aug 2014 21 Jul 2014 09 Sep 2014 0.7 Tunai
22 May 2014 24 Apr 2014 10 Jun 2014 0.7 Tunai
21 Feb 2014 02 Jan 2014 11 Mar 2014 0.66 Tunai
22 Nov 2013 17 Oct 2013 10 Dec 2013 0.66 Tunai
23 Aug 2013 15 Jul 2013 10 Sep 2013 0.66 Tunai
23 May 2013 25 Apr 2013 11 Jun 2013 0.66 Tunai
22 Feb 2013 02 Jan 2013 12 Mar 2013 0.61 Tunai
23 Nov 2012 17 Oct 2012 11 Dec 2012 0.61 Tunai
24 Aug 2012 16 Jul 2012 11 Sep 2012 0.61 Tunai
24 May 2012 26 Apr 2012 12 Jun 2012 0.61 Tunai
24 Feb 2012 03 Jan 2012 13 Mar 2012 0.57 Tunai
25 Nov 2011 21 Oct 2011 13 Dec 2011 0.57 Tunai
26 Aug 2011 18 Jul 2011 13 Sep 2011 0.57 Tunai
26 May 2011 28 Apr 2011 14 Jun 2011 0.57 Tunai
25 Feb 2011 03 Jan 2011 15 Mar 2011 0.54 Tunai
26 Nov 2010 21 Oct 2010 14 Dec 2010 0.54 Tunai
27 Aug 2010 19 Jul 2010 14 Sep 2010 0.54 Tunai
27 May 2010 22 Apr 2010 15 Jun 2010 0.54 Tunai
19 Feb 2010 04 Jan 2010 09 Mar 2010 0.49 Tunai
20 Nov 2009 22 Oct 2009 08 Dec 2009 0.49 Tunai
21 Aug 2009 20 Jul 2009 08 Sep 2009 0.49 Tunai
21 May 2009 23 Apr 2009 09 Jun 2009 0.49 Tunai
20 Feb 2009 05 Jan 2009 10 Mar 2009 0.46 Tunai
21 Nov 2008 16 Oct 2008 09 Dec 2008 0.46 Tunai
22 Aug 2008 21 Jul 2008 09 Sep 2008 0.46 Tunai
22 May 2008 24 Apr 2008 10 Jun 2008 0.46 Tunai
22 Feb 2008 02 Jan 2008 11 Mar 2008 0.415 Tunai
23 Nov 2007 18 Oct 2007 11 Dec 2007 0.415 Tunai
24 Aug 2007 16 Jul 2007 11 Sep 2007 0.415 Tunai
24 May 2007 26 Apr 2007 12 Jun 2007 0.415 Tunai
23 Feb 2007 03 Jan 2007 13 Mar 2007 0.375 Tunai
24 Nov 2006 19 Oct 2006 12 Dec 2006 0.375 Tunai
25 Aug 2006 18 Jul 2006 12 Sep 2006 0.375 Tunai
25 May 2006 27 Apr 2006 13 Jun 2006 0.375 Tunai
18 Nov 2005 20 Oct 2005 13 Dec 2005 0.33 Tunai
19 Aug 2005 18 Jul 2005 13 Sep 2005 0.33 Tunai
13 May 2005 28 Apr 2005 07 Jun 2005 0.33 Tunai
11 Feb 2005 04 Jan 2005 08 Mar 2005 0.285 Tunai
12 Nov 2004 22 Oct 2004 07 Dec 2004 0.285 Tunai
13 Aug 2004 20 Jul 2004 07 Sep 2004 0.285 Tunai
14 May 2004 22 Apr 2004 08 Jun 2004 0.285 Tunai
12 Feb 2004 05 Jan 2004 09 Mar 2004 0.24 Tunai
14 Nov 2003 16 Oct 2003 09 Dec 2003 0.24 Tunai
15 Aug 2003 22 Jul 2003 09 Sep 2003 0.24 Tunai
16 May 2003 24 Apr 2003 10 Jun 2003 0.24 Tunai
13 Feb 2003 06 Jan 2003 11 Mar 2003 0.205 Tunai
15 Nov 2002 15 Oct 2002 10 Dec 2002 0.205 Tunai
16 Aug 2002 15 Jul 2002 10 Sep 2002 0.205 Tunai
17 May 2002 25 Apr 2002 11 Jun 2002 0.205 Tunai
14 Feb 2002 02 Jan 2002 12 Mar 2002 0.18 Tunai
16 Nov 2001 18 Oct 2001 11 Dec 2001 0.18 Tunai
17 Aug 2001 16 Jul 2001 11 Sep 2001 0.18 Tunai
18 May 2001 26 Apr 2001 12 Jun 2001 0.36 Tunai
15 Feb 2001 02 Jan 2001 13 Mar 2001 0.32 Tunai
17 Nov 2000 16 Oct 2000 12 Dec 2000 0.32 Tunai
18 Aug 2000 17 Jul 2000 12 Sep 2000 0.32 Tunai
19 May 2000 19 Apr 2000 13 Jun 2000 0.32 Tunai
11 Feb 2000 03 Jan 2000 07 Mar 2000 0.28 Tunai
12 Nov 1999 18 Oct 1999 07 Dec 1999 0.28 Tunai
13 Aug 1999 19 Jul 1999 07 Sep 1999 0.28 Tunai
14 May 1999 22 Apr 1999 08 Jun 1999 0.28 Tunai
11 Feb 1999 04 Jan 1999 09 Mar 1999 0.25 Tunai
13 Nov 1998 19 Oct 1998 08 Dec 1998 0.25 Tunai
14 Aug 1998 20 Jul 1998 08 Sep 1998 0.25 Tunai
15 May 1998 23 Apr 1998 09 Jun 1998 0.25 Tunai
12 Feb 1998 02 Jan 1998 10 Mar 1998 0.22 Tunai
14 Nov 1997 20 Oct 1997 09 Dec 1997 0.22 Tunai
15 Aug 1997 21 Jul 1997 09 Sep 1997 0.22 Tunai
16 May 1997 24 Apr 1997 10 Jun 1997 0.22 Tunai
13 Feb 1997 02 Jan 1997 11 Mar 1997 0.19 Tunai
15 Nov 1996 21 Oct 1996 10 Dec 1996 0.19 Tunai
16 Aug 1996 15 Jul 1996 10 Sep 1996 0.19 Tunai
17 May 1996 25 Apr 1996 11 Jun 1996 0.38 Tunai
15 Feb 1996 02 Jan 1996 12 Mar 1996 0.33 Tunai
10 Nov 1995 16 Oct 1995 05 Dec 1995 0.33 Tunai
11 Aug 1995 17 Jul 1995 05 Sep 1995 0.33 Tunai
10 May 1995 27 Apr 1995 06 Jun 1995 0.33 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 1.24 1 0.61
2024 4.91 4 3.40
2023 4.70 4 3.00
2022 4.45 4 2.52
2021 4.19 4 2.45
2020 3.98 4 2.53
2019 3.75 4 2.57
2018 3.54 4 2.74
2017 3.32 4 2.38
2016 3.15 4 2.73
2015 2.95 4 2.87
2014 2.76 4 2.64
2013 2.59 4 2.83
2012 2.40 4 3.42
2011 2.25 4 3.43
2010 2.11 4 3.41
2009 1.93 4 3.00
2008 1.80 4 3.00
2007 1.62 4 2.43
2006 1.13 3 1.70
2005 1.28 4 2.12
2004 1.10 4 1.73
2003 0.925 4 1.79
2002 0.795 4 1.48
2001 1.04 4 1.76
2000 1.24 4 2.36
1999 1.09 4 2.34
1998 0.970 4 2.31
1997 0.850 4 2.58
1996 1.09 4 4.38
1995 0.990 3 4.63
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda